Jump Financial, LLC 89bio, Inc. Transaction History

Jump Financial, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.36 - $9.66 $725,673 - $952,447	-98,597 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $382,269 - $570,004	52,294 Added 112.94%	98,597 $789,000
Q1 2024 May 13, 2024	BUY	$8.13 - $13.77 $376,443 - $637,592	46,303 New	46,303 $538,000
Q1 2023 Oct 21, 2024	SELL	$10.48 - $16.94 $638,462 - $1.03 Million	-60,922 Reduced 61.79%	37,675 $573,000
Q1 2023 May 03, 2023	SELL	$10.48 - $16.94 $11,601 - $18,752	-1,107 Reduced 2.85%	37,675 $573,000
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $214,076 - $493,694	38,782 New	38,782 $493,000
Q2 2022 Aug 09, 2022	SELL	$2.09 - $4.02 $34,903 - $67,134	-16,700 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$3.45 - $14.99 $57,615 - $250,333	16,700 New	16,700 $63,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $369M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.